OncBioMune Pharmaceuticals
Baton Rouge, US · Nevada corporation
OncBioMune is a clinical-stage biopharmaceutical company developing novel cancer immunotherapy products using proprietary vaccine technology designed to stimulate immune response against cancer cells. The company focuses on treatments for prostate cancer and other oncology indications, with its lead product in Phase 2 development.
Founders & leadership
DJ
Dr. Jonathan HeadChairman of the Board, Chief Scientific Officer
AK
Andrew KucharchukExecutive
DB
Dr. Brian BarnettChief Executive Officer
RE
Robert Elliott, Jr.Named on SEC filing
Reported raises · per SEC filings
Form D private placements$2.4M disclosed across 5 of 6 rounds · 2015–2022
▶$3.4MofferedDec 2022 · 12 investors · BiotechnologyRule 506(c)
▶$3.4MofferedDec 2022 · 12 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Andrew KucharchukDirector
- Matthew W. Schwartz, MDDirector
- Mick RuxinExecutive Officer, Director
- Jeffrey BuschDirector
- Danica HolleyDirector
- Yvonne ForsDirector
- Thomas ChilcottExecutive Officer
- Offering amount
- $3.4M
- Minimum investment
- $100K
- Sales commissions
- $300K
- Placement agents
- Joseph Gunnar & Co. LLC
- First sale
- Nov 2022
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06c
▶$400KraisedFeb 2021 · 4 investors · BiotechnologyRule 506(c)
▶$400KraisedFeb 2021 · 4 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Yvonne ForsDirector
- Jeffrey BuschDirector
- Andrew KucharchukDirector
- Thomas Chilcott, IIIExecutive Officer
- Mick Ruxin, MDExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $400K
- Minimum investment
- $100K
- First sale
- Jan 2021
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06c
▶$184.9KraisedMay 2019 · 36 investors · PharmaceuticalsRule 506(b)
▶$184.9KraisedMay 2019 · 36 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Brian Barnett, M.D.Executive Officer
- ROBERT N HOLCOMBDirector
- DANIEL S HOVERMANDirector
- ANDREW A KUCHARCHUKExecutive Officer
- JONATHAN F. HEAD, PH.DDirector
- CHARLES L RICE, JRDirector
- Offering amount
- $184.9K
- Amount sold
- $184.9K
- First sale
- Apr 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.2MraisedOct 2018 · 4 investors · BiotechnologyRule 506(b)
▶$1.2MraisedOct 2018 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan F. HeadExecutive Officer, Director
- Robert N. HolcombDirector
- Charles L. Rice, Jr.Director
- Andrew KucharchukExecutive Officer
- Daniel S. HovermanDirector
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- First sale
- Sep 2018
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$95KraisedDec 2015 · 1 investors · PharmaceuticalsRule 506(b)
▶$95KraisedDec 2015 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Charles L. RiceDirector
- Daniel S. HovermanDirector
- Robert ElliottDirector
- Andrew A. KucharchukExecutive Officer, Director
- Jonathan F. HeadExecutive Officer, Director
- Offering amount
- $11.1M
- Amount sold
- $95K
- First sale
- Dec 2015
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$515.7KraisedOct 2015 · 38 investors · PharmaceuticalsRule 506(b)
▶$515.7KraisedOct 2015 · 38 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan Frederick HeadExecutive Officer, Director
- Robert Elliott, Jr.Executive Officer, Director
- Andrew KucharchukExecutive Officer, Director
- Offering amount
- $750K
- Amount sold
- $515.7K
- First sale
- Sep 2015
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlapNexImmune9 shared keywordsNexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses. Its programs target oncology, autoimmune disorders, and infectious disease using formats including adoptive cell therapy (AIM ACT) and direct injection (AIM INJ).
Evommune9 shared keywordsEvommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief. The company runs discovery and development programs with a focus on immunology.
Primmune Therapeutics9 shared keywordsPrimmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
Inimmune8 shared keywordsInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
Avammune8 shared keywordsAvammune is a biotech company developing novel therapeutic modalities to address hard-to-treat cancers with distinct mechanisms of action. The company focuses on patient-centric oncology drug discovery, emphasizing improved compliance, ease of administration, and greater accessibility.
Immunome8 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Bioworld7 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with OncBioMune Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does OncBioMune Pharmaceuticals do?
- OncBioMune is a clinical-stage biopharmaceutical company developing novel cancer immunotherapy products using proprietary vaccine technology designed to stimulate immune response against cancer cells. The company focuses on treatments for prostate cancer and other oncology indications, with its lead product in Phase 2 development.
- Who founded OncBioMune Pharmaceuticals?
- OncBioMune Pharmaceuticals was founded by Dr. Jonathan Head.
- How much funding has OncBioMune Pharmaceuticals raised?
- OncBioMune Pharmaceuticals has disclosed $2.4M raised across 5 of its 6 known rounds.
- Where is OncBioMune Pharmaceuticals headquartered?
- OncBioMune Pharmaceuticals is headquartered in Baton Rouge, US.